| Jamie L Mull, MD | |
|
421 Chestnut St, Evansville, IN 47713 | |
| (812) 426-9355 | |
| (812) 858-4539 |
| Full Name | Jamie L Mull |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 11 Years |
| Location | 421 Chestnut St, Evansville, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467892166 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 01080290A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Deaconess Hospital Inc | Evansville, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Deaconess Clinic Inc | 3375610116 | 337 |
News Archive
The mechanism by which a herpes virus invades cells has remained a mystery to scientists seeking to thwart this family of viruses. New research funded by the National Institutes of Health and published online in advance of print in Nature Structural & Molecular Biology reveals the unusual structure of the protein complex that allows a herpes virus to invade cells. This detailed map of a key piece of the herpes virus "cell-entry machinery" gives scientists a new target for antiviral drugs.
In this webinar, you will review best practices, short cuts, and tricks-of-the-trade to become more successful in developing effective HPLC methods (potency and ICH-compliant stability-indicating assays) using method templates and universal generic gradient methods.
"Starting in July, a special high-risk pool will offer coverage to uninsured people with pre-existing health conditions at a cost similar to what everyone else pays. It's the first test of whether the administration can deliver on Obama's vision within the budget Congress set. But some vulnerable patients are probably going to feel a little cheated."
TherapeuticsMD, Inc., a women's healthcare company, announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal women.
Anacor Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price of $5.00 per share.
› Verified 1 days ago
| Entity Name | Deaconess Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619123585 PECOS PAC ID: 3375610116 Enrollment ID: O20080922000145 |
News Archive
The mechanism by which a herpes virus invades cells has remained a mystery to scientists seeking to thwart this family of viruses. New research funded by the National Institutes of Health and published online in advance of print in Nature Structural & Molecular Biology reveals the unusual structure of the protein complex that allows a herpes virus to invade cells. This detailed map of a key piece of the herpes virus "cell-entry machinery" gives scientists a new target for antiviral drugs.
In this webinar, you will review best practices, short cuts, and tricks-of-the-trade to become more successful in developing effective HPLC methods (potency and ICH-compliant stability-indicating assays) using method templates and universal generic gradient methods.
"Starting in July, a special high-risk pool will offer coverage to uninsured people with pre-existing health conditions at a cost similar to what everyone else pays. It's the first test of whether the administration can deliver on Obama's vision within the budget Congress set. But some vulnerable patients are probably going to feel a little cheated."
TherapeuticsMD, Inc., a women's healthcare company, announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal women.
Anacor Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price of $5.00 per share.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jamie L Mull, MD Po Box 1510, Evansville, IN 47706-1510 Ph: (812) 426-9355 | Jamie L Mull, MD 421 Chestnut St, Evansville, IN 47713 Ph: (812) 426-9355 |
News Archive
The mechanism by which a herpes virus invades cells has remained a mystery to scientists seeking to thwart this family of viruses. New research funded by the National Institutes of Health and published online in advance of print in Nature Structural & Molecular Biology reveals the unusual structure of the protein complex that allows a herpes virus to invade cells. This detailed map of a key piece of the herpes virus "cell-entry machinery" gives scientists a new target for antiviral drugs.
In this webinar, you will review best practices, short cuts, and tricks-of-the-trade to become more successful in developing effective HPLC methods (potency and ICH-compliant stability-indicating assays) using method templates and universal generic gradient methods.
"Starting in July, a special high-risk pool will offer coverage to uninsured people with pre-existing health conditions at a cost similar to what everyone else pays. It's the first test of whether the administration can deliver on Obama's vision within the budget Congress set. But some vulnerable patients are probably going to feel a little cheated."
TherapeuticsMD, Inc., a women's healthcare company, announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal women.
Anacor Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price of $5.00 per share.
› Verified 1 days ago
Jon C Davis, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 120 Se 4th St, Evansville, IN 47708 Phone: 812-426-9355 Fax: 812-858-4539 | |
Vanessa M Mischler, NP Dermatology Medicare: Medicare Enrolled Practice Location: 1212 Professional Blvd Ste B, Evansville, IN 47714 Phone: 812-401-9030 Fax: 812-401-9033 | |
Robert William Martin Iii, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 421 Chestnut St, Evansville, IN 47713 Phone: 812-426-9355 Fax: 812-858-4539 | |
Jeffrey Keith Moore, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 421 Chestnut St, Evansville, IN 47713 Phone: 812-426-9355 Fax: 812-858-4539 | |
Dr. Shari Lyn Barrett, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3700 Bellemeade Ave, Suite 120, Evansville, IN 47714 Phone: 812-473-0200 Fax: 812-473-3640 | |
David Surprenant, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 120 Se 4th St, Evansville, IN 47708 Phone: 812-463-4306 | |
Dr. Charles P Hudson, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3501 Washington Ave, Evansville, IN 47714 Phone: 812-474-1234 Fax: 812-402-3636 |